Literature DB >> 28057951

Stability of Levodopa/Carbidopa Rectal Suspensions.

Ronald F Donnelly.   

Abstract

Objective: The combination of levodopa and carbidopa (L/C) is used as an effective therapy for treating Parkinson's disease; however when oropharyngeal dysphagia develops or when insertion of an nasogastric tube is not possible, then rectal administration could be used. To reduce compounding workload and establish a beyond use date, this study was conducted to determine the stability of 2 L/C rectal suspension formulations when stored at either 22°C or 5°C.
Methods: Two formulations of L/C rectal suspension were compounded and then packaged in amber polypropylene bottles. Three bottles of each formulation were stored at either 22°C or 5°C and analyzed at 11 time periods. Physical parameters such as caking, ease of resuspending, and pH were also determined at each time period. A validated stability-indicating high-performance liquid chromatography (HPLC) method was used to analyze both active ingredients.
Results: All solutions were easy to resuspend, there were no signs of caking, and there was no significant change in pH over the 35 days of storage at either temperature. The glycerin-based formulation (formulation 1) was less stable at 22°C (10 days) than formulation 2 (24 days). Both rectal suspensions were stable for 35 days when stored at 5°C. Conclusions: The physical compatibility and chemical stability of 2 formulations of L/C rectal suspension packaged in amber polypropylene bottles was determined to be either 10 or 24 days when stored at 22°C or 35 days at 5°C.

Entities:  

Keywords:  carbidopa; drug stability; high-performance liquid chromatography; levodopa; suspension

Year:  2016        PMID: 28057951      PMCID: PMC5199224          DOI: 10.1310/hpj5111-915

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  7 in total

1.  Case report: successful use of rectally administered levodopa-carbidopa.

Authors:  S D Cooper; H A Ismail; C Frank
Journal:  Can Fam Physician       Date:  2001-01       Impact factor: 3.275

2.  Rectal administration of L-dopa.

Authors:  P L Beasley; T A Hare; W H Vogel; S Desimone
Journal:  N Engl J Med       Date:  1973-10-25       Impact factor: 91.245

3.  Absorption of levodopa after rectal administration.

Authors:  T Eisler; N Eng; C Plotkin; D B Calne
Journal:  Neurology       Date:  1981-02       Impact factor: 9.910

4.  Levodopa in hepatic coma.

Authors:  J D Parkes; P Sharpstone; R Williams
Journal:  Lancet       Date:  1970-12-26       Impact factor: 79.321

5.  Compatibility of cholecalciferol, haloperidol, imipramine hydrochloride, levodopa/carbidopa, lorazepam, minocycline hydrochloride, tacrolimus monohydrate, terbinafine, tramadol hydrochloride and valsartan in SyrSpend SF PH4 oral suspensions.

Authors:  H C Polonini; S L Silva; C N Cunha; M A F Brandão; A O Ferreira
Journal:  Pharmazie       Date:  2016-04       Impact factor: 1.267

6.  Development of two stable oral suspensions of levodopa-carbidopa for children with amblyopia.

Authors:  M C Nahata; R S Morosco; L E Leguire
Journal:  J Pediatr Ophthalmol Strabismus       Date:  2000 Nov-Dec       Impact factor: 1.402

7.  Effect of Rectal Levodopa Administration: A Case Report.

Authors:  Jolanda M J Vogelzang; Marianne Luinstra; A Wijnand F Rutgers
Journal:  Case Rep Neurol       Date:  2015-10-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.